CALR c.224A>G ;(p.Y75C)

Variant ID: 19-13050272-A-G

NM_004343.3(CALR):c.224A>G;(p.Y75C)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.

Blood
Sperling, Adam S AS; Guerra, Veronica A VA; Kennedy, James A JA; Yan, Yuanqing Y; Hsu, Joanne I JI; Wang, Feng F; Nguyen, Andrew T AT; Miller, Peter G PG; McConkey, Marie E ME; Quevedo Barrios, Vanessa A VA; Furudate, Ken K; Zhang, Linda L; Kanagal-Shamanna, Rashmi R; Zhang, Jianhua J; Little, Latasha L; Gumbs, Curtis C; Daver, Naval N; DiNardo, Courtney D CD; Kadia, Tapan T; Ravandi, Farhad F; Kantarjian, Hagop H; Garcia-Manero, Guillermo G; Futreal, P Andrew PA; Ebert, Benjamin L BL; Takahashi, Koichi K
Publication Date: 2022-10-20

Variant appearance in text: CALR: Y75C
PubMed Link: 35512188
Variant Present in the following documents:
  • BLOOD_BLD-2021-014956-mmc1.pdf
View BVdb publication page